|Synonyms||U-7265; 5α-Dihydrofluoxymesterone; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-dihydrotestosterone; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-DHT; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-androstan-17β-ol-3-one|
|Drug class||Androgen; Anabolic steroid|
|Chemical and physical data|
|Molar mass||337.454 g/mol g·mol−1|
|3D model (JSmol)|
Dihydrofluoxymesterone (developmental code name U-7265) is an androgen and anabolic steroid (AAS) which was never marketed. It was assessed in the treatment of breast cancer in women in at least one clinical study in the 1970s and showed effectiveness similar to that of other AAS. The drug is the 5α-reduced analogue and metabolite of fluoxymesterone.
- Gordan, G. S. (1976). "Cancer in Man": 499–513. doi:10.1007/978-3-642-66353-6_16.
- Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 504–. ISBN 978-3-642-66353-6.
- Kammerer RC, Merdink JL, Jagels M, Catlin DH, Hui KK (1990). "Testing for fluoxymesterone (Halotestin) administration to man: identification of urinary metabolites by gas chromatography-mass spectrometry". J. Steroid Biochem. 36 (6): 659–66. PMID 2214783.
|This article about a steroid is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|